Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsUpgradesPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.
Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.
